Premium
Scynexis Inc (SCYX)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatm... SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.028 | -2.91666666667 | 0.96 | 0.9677 | 0.8227 | 159829 | 0.89555171 | CS |
| 4 | -0.238 | -20.3418803419 | 1.17 | 1.18 | 0.8227 | 167917 | 0.99710361 | CS |
| 12 | -0.048 | -4.89795918367 | 0.98 | 1.49 | 0.8227 | 216235 | 1.13644725 | CS |
| 26 | -0.528 | -36.1643835616 | 1.46 | 1.66 | 0.8227 | 185222 | 1.2314821 | CS |
| 52 | -0.568 | -37.8666666667 | 1.5 | 3.07 | 0.8227 | 193845 | 1.59314095 | CS |
| 156 | -3.068 | -76.7 | 4 | 5.1475 | 0.8227 | 353703 | 2.48339265 | CS |
| 260 | 0.332 | 55.3333333333 | 0.6 | 11.3 | 0.5 | 401211 | 3.59159386 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
